News Releases

May 27, 2020
Urovant Sciences Appoints James Hindman to Board of Directors
James Hindman , a veteran global and strategic senior financial executive, brings extensive experience in the pharmaceutical, biologics and medical device industries to the Urovant Board Mr. Hindman most recently served as Chief Financial Officer at Allergan until its $70.5B sale to Actavis IRVINE,
Additional Formats
May 14, 2020
Urovant Sciences Presents Positive Clinical Efficacy & Safety Data on Lead Drug Candidate Vibegron at Virtual American Urological Association Annual Meeting
52-Week Post Hoc Analysis Shows Vibegron Patients Had Statistically Significant, Sustained Reduction in UUI and Total Incontinence Episodes Compared to Active Control IRVINE, Calif. & BASEL, Switzerland --(BUSINESS WIRE)--May 14, 2020-- Urovant Sciences (Nasdaq: UROV) announced today that data from
Additional Formats
February 13, 2020
Urovant Sciences Reports 2019 Third Fiscal Quarter Financial Results
IRVINE, Calif. & BASEL, Switzerland --(BUSINESS WIRE)--Feb. 13, 2020-- Urovant Sciences (Nasdaq: UROV) today reported financial results for the 2019 third fiscal quarter ended December 31, 2019 . Recent Business Highlights Submitted a New Drug Application for vibegron for the treatment of patients
Additional Formats
Displaying 1 - 10 of 12